Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $79.8571.

A number of brokerages recently issued reports on TARS. Zacks Research upgraded Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. Mizuho initiated coverage on shares of Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price on the stock. Guggenheim lifted their price target on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $51.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 6th.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 7,397 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the sale, the insider owned 38,958 shares in the company, valued at $3,120,535.80. This trade represents a 15.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total transaction of $495,060.00. Following the sale, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at $70,792,837.41. This represents a 0.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 8.97% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TARS. TFG Asset Management GP Ltd raised its position in shares of Tarsus Pharmaceuticals by 40.1% in the 2nd quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock worth $10,128,000 after acquiring an additional 71,530 shares in the last quarter. Capricorn Fund Managers Ltd purchased a new position in Tarsus Pharmaceuticals in the third quarter valued at about $14,264,000. Allianz Asset Management GmbH purchased a new position in Tarsus Pharmaceuticals in the second quarter valued at about $227,000. Jump Financial LLC raised its holdings in Tarsus Pharmaceuticals by 385.9% in the second quarter. Jump Financial LLC now owns 237,117 shares of the company’s stock worth $9,606,000 after purchasing an additional 188,317 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Tarsus Pharmaceuticals during the second quarter valued at about $19,095,000. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ TARS opened at $68.15 on Wednesday. The business’s 50 day moving average is $78.32 and its two-hundred day moving average is $65.11. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.29 and a quick ratio of 4.25. Tarsus Pharmaceuticals has a 1-year low of $38.51 and a 1-year high of $85.25. The stock has a market capitalization of $2.89 billion, a P/E ratio of -33.74, a PEG ratio of 0.98 and a beta of 0.59.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.05. The business had revenue of $118.70 million during the quarter, compared to analyst estimates of $114.22 million. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%. As a group, research analysts expect that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.